Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 10/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 9/20 | 0.50 |
| ▸ | NQO2 | P16083 | 8/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17361636 | 0.84 | HTR6 (0.49) | DRD2 | |
| SCHEMBL29981098 | 0.81 | MAPT (0.45) | DRD2 | |
| SCHEMBL388481 | 0.80 | ESR1 (0.48) | MTNR1AMTNR1BNQO2DRD2HTR2C | |
| SCHEMBL485349 | 0.79 | BACE1 (0.43) | DRD2 | |
| SCHEMBL485350 | 0.79 | BACE1 (0.43) | DRD2 | |
| SCHEMBL7354890 | 0.78 | MTNR1A (0.43) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL17361953 | 0.78 | KDM4C (0.51) | — | |
| SCHEMBL6491979 | 0.78 | MTNR1A (0.46) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL17361826 | 0.78 | KDM4C (0.51) | — | |
| SCHEMBL22534289 | 0.78 | ACACB (0.47) | DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919335-B2 | Administering a therapeutically effective amount of a heterocyclic compound to the patient for the treatment of inosine monophosphate dehydrogenase associated disorders, such as allograft rejection | BRISTOL-MYERS SQUIBB CO. (US) | 2005-07-19 | — | — | US | disclosed |
| US-20020040022-A1 | Heterocycles that are inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY | 2002-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040022-A1 | Heterocycles that are inhibitors of IMPDH enzyme | XDH, IMPDH1, IMPDH2 | MTNR1A 2950/4885MTNR1B 3200/4885NQO2 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.